Procedure for Stability Studies of Pediatric Drug Formulations According to US FDA and EMA Guidelines

1) Purpose

The purpose of this SOP is to outline the procedure for conducting stability testing for pediatric drug formulations in accordance with US FDA and European Medicines Agency (EMA) guidelines. This ensures that pediatric formulations retain their safety, quality, and efficacy throughout their shelf life, meeting all regulatory standards.

2) Scope

This SOP applies to all personnel involved in the stability testing of pediatric drug formulations, including teams in formulation development, quality control, and regulatory affairs.

3) Responsibilities

Formulation Development Team: Responsible for designing pediatric formulations that consider taste, dosage form, and excipient selection suitable for children.
Stability Study Team: Responsible for planning and conducting stability studies according to the defined protocol and regulatory guidelines.
Regulatory Affairs Team: Responsible for ensuring all stability data complies with FDA

and EMA requirements and is properly documented for regulatory submissions.

4) Procedure

4.1 Development of Stability Protocol

4.1.1 Create a stability testing protocol specific to pediatric formulations, addressing factors such as flavor stability, dosage uniformity, microbial limits, and excipient interactions.

4.1.2 Define appropriate storage conditions (e.g., room temperature, refrigerated) and testing intervals (e.g., 0, 3, 6, 12 months) based on FDA and EMA guidelines.

4.2 Sample Preparation and Storage

4.2.1 Prepare samples in their final pediatric packaging (e.g., oral syringes, droppers) for stability testing.

4.2.2 Store samples under the specified conditions (e.g., controlled room temperature, refrigerated) and monitor storage conditions continuously to ensure compliance.

4.3 Execution of Stability Testing

4.3.1 Conduct stability tests at each defined interval, including assessments for appearance, taste, dissolution, pH, assay, and microbial content.

4.3.2 Record all findings in a systematic manner, ensuring data integrity and traceability according to the approved protocol.

4.4 Data Evaluation and Reporting

4.4.1 Review and analyze stability data to detect any trends, deviations, or failures that could impact product quality or safety.

4.4.2 Prepare a comprehensive stability report, including all test results, observations, and conclusions, and submit it to the appropriate regulatory authorities for evaluation.

5) Abbreviations, if any

FDA: US Food and Drug Administration
EMA: European Medicines Agency

6) Documents, if any

6.1 Pediatric stability testing protocols
6.2 Raw data sheets
6.3 Stability reports
6.4 Regulatory submission documentation

7) Reference, if any

FDA Guidance for Industry: Stability Testing of Pediatric Formulations, EMA Guidelines on Pediatric Medicines Development

8) SOP Version

Version 1.0